Message from RPS: COVID-19

Dear All,

Hope you and your teams are keeping well and staying safe.

Thank you for the calls and emails over the last couple of weeks. Your insights and inputs have and continue to be valuable. We have been submitting your asks to government and the NHS on an ongoing basis and trying ourselves to help with guidance via our hub page.

I am keen to still get more feedback from you to be able to lobby the government and national NHS teams on. I know calls on a regular basis are difficult, so please feel free to email your thoughts and suggestions to me directly when you can. My email is [email protected]

Thanks for all you and your teams for the fantastic work on the frontline.

Stay safe.

Ravi

Ravi Sharma | Director of England

Pharmacy and Member Experience

Royal Pharmaceutical Society

Latest News

By BOPA Research Committee on 25th April 2024

Survey: Pharmacogenomic Panel Testing in Cancer: UK Oncology Professionals

Please consider completing our BOPA member survey on the use of pharmacogenomic panel testing in people with solid tumours. Survey information I’m a pharmacist and pre-doctoral research fellow researching the…

Read article
By BOPA Research committee on 25th April 2024

NIHR Associate Principal Investigator (PI) Scheme is continuing to host Research Learning Lectures

The NIHR Associate Principal Investigator (PI) Scheme is continuing to host the Research Learning Lectures; a series of lectures for anyone in Health and Social Care interested in learning more about research.…

Read article
By BOPA on 16th April 2024

Abstract Submission for #BOPA2024 is NOW OPEN

Abstract Submission for the 27th Annual BOPA Conference in 2024 is now OPEN   Delegates are invited to present results of their clinical and technical work as a poster with…

Read article
By BOPA Research Subcommittee on 15th April 2024

Survey: Service Evaluation on Carboplatin Variation in UK

We invite members to complete this service evaluation to understand national variations in carboplatin dosing for adult patients receiving SACTs. We are looking at whether we can standardise carboplatin protocols…

Read article